From GlobeNewswire: 2025-03-06 16:00:00

Molecular Partners announced plans for Radio-DARPin MP0712 to enter a first-in-human study in 2025 pending regulatory clearance. The partnership with Orano Med on Radio-DARPin programs has expanded to ten programs. Phase 1/2a clinical data for MP0533 show improved response rates with additional dosing optimization planned for 2025.

The company reported a strong financial position with CHF 149 million in cash and short-term deposits at the end of 2024. A conference call is scheduled for March 7, 2025, at 2.00 pm CET to discuss corporate highlights and financial results for the full year 2024. Molecular Partners aims to advance its Radio-DARPin platform with innovative therapeutics for oncology.

Molecular Partners is preparing an Investigational New Drug (IND) application for MP0712 targeting DLL3, a key protein in small cell lung cancer. The company has also developed a Radio-DARPin platform for a broad range of tumor targets. The partnership with Orano Med aims to develop up to ten radiotherapy programs using 212Pb-based RDTs.

MP0533, a novel tetraspecific T cell engager, has shown promising results in a Phase 1/2a clinical trial for AML. An amended dosing scheme is planned to enhance response rates and depth in 2025. Molecular Partners’ Switch-DARPin platform aims to increase the safety and potency of T cell engagers for oncology treatments.

Molecular Partners’ financial report for 2024 shows total revenues of CHF 5.0 million and operating expenses of CHF 66.2 million. The company’s cash position of CHF 149.4 million is expected to support operations well into 2027. Plans for 2025 include total operating expenses of CHF 55-65 million.

The company’s DARPin therapeutics are designed to address medical challenges with unique solutions. Molecular Partners focuses on oncology programs and collaborates with leading pharmaceutical companies. Forward-looking statements caution potential risks and uncertainties in the development and commercialization of product candidates.



Read more at GlobeNewswire:: Molecular Partners Reports Highlights from Q4 2024 and Key